Biosimilar Approval Is New Focus In Senate Critique Of FDA Guidance Policy
This article was originally published in The Pink Sheet Daily
Commissioner Hamburg describes a Catch-22, warning that pressure to finalize guidances faster without more resources could result in fewer discretionary guidances, disappointing stakeholders.
You may also be interested in...
Pfizer Says FDA Draft Guidance Is Just Fine; Congress Should Be Patient
In an unusual move, industry rep indicates comfort with draft guidance implementing biosimilar pathway.
FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals
From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.